Economic burden of prescriptive inadequacy in the management of osteoarthritis in Italy

Il burden economico dell’inappropriatezza prescrittiva nella gestione dell’osteoartrite in Italia

Authors

  • Michele Basile School of Health Economics and Management (ALTEMS), Dipartimento di Economia Sanitaria, Roma and Catholic University of Sacred Heart (UCSC), Dipartimento di Economia Sanitaria, Roma - Italy
  • Filippo Rumi School of Health Economics and Management (ALTEMS), Dipartimento di Economia Sanitaria, Roma and Catholic University of Sacred Heart (UCSC), Dipartimento di Economia Sanitaria, Roma - Italy
  • Marco Palmeri School of Health Economics and Management (ALTEMS), Dipartimento di Economia Sanitaria, Roma and Catholic University of Sacred Heart (UCSC), Dipartimento di Economia Sanitaria, Roma - Italy
  • Ivano Mattozzi Casa della Salute di Bagnoregio, Dipartimento Cure Primarie, ASL Viterbo, Viterbo - Italy
  • Lamberto Manzoli University of Ferrara, Dipartimento di Scienze Mediche, Ferrara - Italy
  • Massimo Mammuccari Primary Care Unit ASL RM 1, Roma - Italy
  • Sergio Gigliotti Primary Care Unit ASL NA1 Centro, Napoli - Italy
  • Roberto Bernabei Policlinico Universitario A. Gemelli, Catholic University of Sacred Heart, Roma - Italy
  • Americo Cicchetti School of Health Economics and Management (ALTEMS), Dipartimento di Economia Sanitaria, Roma and Catholic University of Sacred Heart (UCSC), Dipartimento di Economia Sanitaria, Roma - Italy

DOI:

https://doi.org/10.33393/grhta.2020.2130

Keywords:

Budget Impact Analysis, Disease management, Economic evaluation, Osteoarthritis, Peripheral neuropathic pain

Abstract

Introduction: Osteoarthritis (OA) is a common chronic joint disease characterized by pain, deformity, instability, reduction of motion and function. It is one of the main causes of disability in older adults, affecting about 10% of men and 18% of women over the age of sixty. There are several Guidelines that support the general clinical decision-making process. However, it is necessary to define an integrated management model for patients with OA to ensure an appropriate and quality healthcare.

Methods: The objective of the analysis is to determine the economic burden linked to the prevalence and incidence of OA in the acute and chronic phases from the perspective of the National Health Service (NHS) and the entire society. A comparison was made between the management according to the clinical practice and the appropriate management according to National and International Guidelines, determining for each scenario the level of resources absorbed.

Results: Patients who started a nonsteroidal anti-inflammatory drug (NSAID)-based therapy in clinical practice resulted in a higher absorption of resources of €363.87 than the same patient managed by referring to National and International Guidelines.

Conclusions: OA is associated with a high economic burden and it is a priority problem for public health internationally. The savings resulting from our research, if generalized to the entire Italian population, would lead to a significant reduction of OA economic burden, thus allowing a reallocation of the available resources to other NHS’ sectors.

Downloads

Download data is not yet available.

References

Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. https://doi.org/10.1016/j.joca.2019.06.011 PMID:31278997

Ferreira de Meneses S, Rannou F, Hunter DJ. Osteoarthritis guidelines: barriers to implementation and solutions. Ann Phys Rehabil Med. 2016;59(3):170-173. https://doi.org/10.1016/j.rehab.2016.01.007 PMID:26947895

Roseti L, Desando G, Cavallo C, Petretta M, Grigolo B. Articular cartilage regeneration in osteoarthritis. Cells. 2019;8(11):1305. https://doi.org/10.3390/cells8111305 PMID:31652798

Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759. https://doi.org/10.1016/S0140-6736(19)30417-9 PMID:31034380

World Health Organization. Chronic rheumatic conditions. Available online at: https://www.who.int/chp/topics/rheumatic/en/ (data ultimo accesso 25/06/2020)

Anthony D. Woolf BP. Burden of major musculoskeletal conditions. 2003. Available online at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2572542/pdf/14710506.pdf (data ultimo accesso 25/06/2020)

Osservatorio Malattie Rare (OMAR). Available online at: https://www.osservatoriomalattierare.it/news/attualita/13084-annuario-istat-2017-il-39-degli-italiani-e-affetto-da-una-malattia-cronica (data ultimo accesso 25/06/2020)

Epicentro ISS. Artriti. Aspetti epidemiologici. Available online at: https://www.epicentro.iss.it/artriti/epidemiologia (data ultimo accesso 25/06/2020)

Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697-1707. https://doi.org/10.1002/art.34453PMID:22392533

Ariani A, Manara M, Fioravanti A, et al. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo. 2019;71(S1):5-21. https://doi.org/10.4081/reumatismo.2019.1188 PMID:31948191

Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies. Semin Arthritis Rheum. 2015;44(5):531-541. https://doi.org/10.1016/j.semarthrit.2014.10.012 PMID:25511476

Ong KL, Runa M, Lau E, Altman RD. Cost-of-illness of knee osteoarthritis: potential cost savings by not undergoing arthroplasty within the first 2 years. Clinicoecon Outcomes Res. 2019;11:245-255. https://doi.org/10.2147/CEOR.S170119 PMID:30936730

PDTA Osteoartrosi-Regione Friuli Venezia Giulia. Available online at: https://www.regione.fvg.it/rafvg/export/sites/default/RAFVG/salute-sociale/sistema-sociale-sanitario/FOGLIA52/allegati/2706206_Pubblicazione_PDTA_OA_e_OP-2016_1.pdf (data ultimo accesso 25/06/2020)

Ruggeri M, Basile M, Armuzzi A, Cicchetti A. Analisi organizzativa e di budget dell’introduzione di vedolizumab vs terapie tradizionali in Colite Ulcerosa e Morbo di Crohn: implicazioni economiche nel confronto con adalimumab, infliximab e golimumab. Glob Reg Health Technol Assess. 2017;4(1):88-99. https://doi.org/10.5301/grhta.5000258

Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther. 2011;33(12):1914-1931. https://doi.org/10.1016/j.clinthera.2011.10.019 PMID:22088416

Kocak AO. Intradermal mesotherapy versus systemic therapy in the treatment of musculoskeletal pain: A prospective randomized study. Am J Emerg Med. 2019;37(11):2061-2065. https://doi.org/10.1016/j.ajem.2019.02.042 PMID:30876777

Mammucari M, Gatti A, Maggiori S, Bartoletti CA, Sabato AF. Mesotherapy, definition, rationale and clinical role: a consensus report from the Italian Society of Mesotherapy. Eur Rev Med Pharmacol Sci. 2011;15(6):682-694. PMID:21796873

Additional Files

Published

2020-12-10

How to Cite

Basile, M., Rumi, F., Palmeri, M., Mattozzi, I., Manzoli, L., Mammuccari, M., Gigliotti, S., Bernabei, R., & Cicchetti, A. (2020). Economic burden of prescriptive inadequacy in the management of osteoarthritis in Italy: Il burden economico dell’inappropriatezza prescrittiva nella gestione dell’osteoartrite in Italia. Global and Regional Health Technology Assessment, 7(1), 101–108. https://doi.org/10.33393/grhta.2020.2130

Issue

Section

Original Research Articles

Categories

Received 2020-04-14
Accepted 2020-09-23
Published 2020-12-10

Metrics

Most read articles by the same author(s)

1 2 > >>